It's something I've written about a few times now, BREXIT and the uncertainties that surround it all for our Pharma/Healthcare industry.
Surely there is one common goal at the end of all this and that is that patients aren't affected negatively. Whether that be UK nationals no longer being able to access healthcare aboard - or vice versa. Or, if we can no longer collaborate in major medical studies, getting left behind our peers across the continent.
Thankfully, the Alliance has outlined this as being one of the key five areas of priority for the BREXIT negotiations...
The Brexit Health Alliance is warning that patients could be at risk if their interests are not protected in negotiations over the UK’s departure from the European Union. The recently-formed group, which consists of a range of NHS, medical research, industry, patients and public health organisations, is urging negotiators to ensure that issues such as healthcare research and access to new medicines are given prominence during talks.